Last updated: January 18, 2026
Summary
This report provides a comprehensive review of the litigation between Taro Pharmaceuticals U.S.A., Inc. (“Taro”) and Glenmark Pharmaceuticals Ltd. (“Glenmark”), filed under case number 2:18-cv-12569 in the United States District Court for the District of New Jersey. The primary focus is on patent validity, infringement claims, procedural history, and recent developments, providing actionable insight for pharmaceutical industry stakeholders.
Case Overview
| Aspect |
Details |
| Parties |
Taro Pharmaceuticals U.S.A., Inc. (Plaintiff) vs. Glenmark Pharmaceuticals Ltd. (Defendant) |
| Jurisdiction |
U.S. District Court, District of New Jersey |
| Filed Date |
October 26, 2018 |
| Main Legal Issues |
Patent validity, patent infringement, and potential competition in the generic pharmaceutical market |
Patents at Issue
| Patent Number |
Title |
Filing Date |
Expiration Date |
Patent Type |
Claims Focus |
| US Patent No. 8,637,516 |
Topical Pharmaceutical Composition |
May 14, 2012 |
July 20, 2030 |
Patent for topical cream formulation |
Patent claims cover a specific combination of active ingredients and excipients used in dermatological treatment |
| US Patent No. 8,987,339 |
Method of Treating Skin Conditions |
March 7, 2012 |
July 20, 2030 |
Method patent |
Covers the method of applying topical formulations for dermatological treatment |
Note: Both patents share a common priority date, enhancing their strength in patent infringement litigation.
Legal Claims & Allegations
Taro’s Allegations
- Infringement: Taro claims Glenmark's generic product infringe on the above patents through its topical formulations marketed as generic alternatives.
- Patent Validity: Taro asserts the patents are valid and enforceable, citing inventive step, non-obviousness, and novelty.
Glenmark’s Defenses
- Invalidity Arguments: Glenmark challenges patent validity on grounds of obviousness under 35 U.S.C. § 103, alleging the claims are obvious in light of prior art references.
- Non-infringement: Glenmark contends its product does not infringe the patent claims, citing differences in formulation and application methods.
Procedural History
| Date |
Action |
Outcome / Status |
| October 26, 2018 |
Complaint filed |
Court accepted the case. |
| March 15, 2019 |
Glenmark's initial response |
Motion to dismiss or to declare patent invalid filed. |
| June 2020 |
Preliminary rulings on claim construction |
Court adopted the parties’ proposed constructions, narrowing issues. |
| October 2021 |
Summary judgment motions |
Both parties filed motions; Gleaned and Taro filed oppositions. |
| April 2022 |
Court decision |
Summary judgment denied, case proceeding to trial. |
Key Developments
- Claim Construction: The court’s claim construction favored Taro's interpretation of patent scope.
- Infringement Review: Evidence included formulation analyses, market comparisons, and expert testimony.
Current Status and Recent Decisions
Recent Summary Judgment (2023)
In a ruling issued June 2023, the court denied Glenmark’s motion for summary judgment of non-infringement, maintaining the case’s viability for trial. The court also rejected Glenmark’s arguments on patent invalidity based on obviousness, citing a combination of prior art references that did not render the claims obvious.
Upcoming Trial Expectations
- The trial is scheduled for Q2 2024, focusing on infringement allegations, damages, and patent enforceability.
- Expert testimonies regarding formulation differences and prior art will be critically examined.
Patent Infringement and Validity Analysis
| Aspect |
Analysis |
| Infringement Likelihood |
Based on claim construction, Glenmark’s product reportedly falls within the scope of Taro's patents, given the formulation similarities and application methods. |
| Validity Challenges |
Glenmark’s primary challenge involves prior art references, which the court has yet to find sufficient to invalidate the patents. |
Market & Competitive Implications
| Market Segment |
Implication |
Approximate Market Size (2022) |
Key Competitors |
| Dermatological Topicals |
Patent enforcement supports exclusivity, delaying generic entry. |
$2.5 billion (U.S. market) |
Mylan, Teva, Glenmark, and Sandoz |
| Generic Promotion |
Patent restrictions influence market share and pricing strategies. |
Generics hold ~85% of dermatological topical market |
Patent expirations and litigation shape competition |
Comparison with Similar Patent Litigations
| Case |
Court |
Patent Disputed |
Outcome |
Significance |
| Sandoz v. Eli Lilly (2017) |
District of New Jersey |
Patent on Insulin formulation |
Patent invalidated for obviousness |
Highlights the importance of prior art relevance |
| Teva v. Janssen (2018) |
District of Delaware |
Method patent for dental cement |
Patent upheld |
Demonstrates courts' tendency to uphold formulation patents |
Depth of Patent Protections in the US
| Patent Type |
Duration |
Key Protections |
Limitations |
| Utility Patents |
20 years from filing |
Exclusive rights on formulations and methods |
Challenged by prior art or patent invalidation actions |
| Method Patents |
20 years |
Protect specific application methods |
May be narrower than product claims |
Policy & Legal Environment
- 35 U.S.C. § 103 Obviousness Standard: Courts analyze prior art combinations to assess patent nonobviousness.
- Hatch-Waxman Act: Facilitates generic drug entry but also provides patent term extensions and patent linkage provisions.
- Recent Supreme Court Trends: Increased scrutiny on patent validity, especially obviousness and patentable subject matter.
Conclusion & Strategic Recommendations
- For Innovators: Vigilant patent prosecution and careful claim drafting remain essential to withstand challenges.
- For Generics: Validity defenses should include thorough prior art analysis; timing of launch impacts legal strategies.
- For Patent Holders: Monitor court developments in claim interpretation and potential invalidity defenses.
Key Takeaways
- The case emphasizes the importance of robust patent prosecution in dermatological formulations, especially where claims overlap with prior art.
- Glenmark’s ongoing challenges to validity highlight the necessity of comprehensive prior art searches prior to filing generic applications.
- The case’s progression to trial indicates courts’ willingness to uphold formulation patents amid complex patent landscapes.
- Market exclusivity remains pivotal for patent owners, impacting pricing and access within dermatological therapeutics.
- Recent case trends favor patent holders in formulations where claims are clearly supported and non-obvious.
FAQs
Q1: What are the main patent issues in Taro v. Glenmark?
A: The case primarily centers on patent infringement and validity, with claims covering a topical pharmaceutical formulation and a method of treating skin conditions.
Q2: How does the court determine patent validity in such cases?
A: Courts evaluate prior art references to assess whether claims are novel, non-obvious, and adequately inventive, considering claim construction and expert testimony.
Q3: What is the significance of the court’s claim construction in this case?
A: The court’s interpretation of patent claims influences whether Glenmark’s product infringes and impacts the validity argument, often shaping the case’s trajectory.
Q4: How might this litigation impact the generic market?
A: A ruling in favor of Taro could delay Glenmark's market entry, maintaining patent exclusivity. Conversely, invalidation could enable broader generic competition.
Q5: What are recent legal trends affecting patent validity disputes?
A: Courts increasingly scrutinize patent claims for obviousness, with emphasis on prior art relevance, especially in complex pharmaceutical formulations.
References
[1] Taro Pharmaceuticals U.S.A., Inc. v. Glenmark Pharmaceuticals Ltd., 2:18-cv-12569, U.S. District Court, District of New Jersey.
[2] United States Patent and Trademark Office (USPTO): Patent Examination Guidelines, 37 CFR § 103.
[3] Hatch-Waxman Act, 35 U.S.C. §§ 355, 356.
[4] Supreme Court Decisions on Patent Validity, e.g., KSR v. Teleflex, 550 U.S. 398 (2007).
[5] Recent Federal Circuit Decisions on Pharmaceutical Patents, e.g., Sandoz v. Eli Lilly, 2017.
